Vanish and see products manufacturer will sell Naldencon and Company in Brazil

Reckitt Benckiser, the British manufacturer of products such as Vanish, Good air and SBP, signed a collaboration agreement to market in Latin America, pharmaceutical drugs Bristol-Myers Squibb.
The partnership with American manufacturer includes the sale to Brazil of anti-flu Naldecon, of Company and antigases ointment for diaper rash Dermodex. In Mexico the sale will be for medicines Tempra, Picot and Graneodin-b. According to the companies, the $ 284 million has a term of three years, in which at the end of the period, Reckitt will have the right to purchase marks. The transaction value was below the expected by the market, he believed that the agreement could be up to $ 750 million.
The partnership made with Reckitt will help Bristol to fill again the Brazilian market, after the closing of the Brazilian factory in 2010. Since then the production is made in Mexico. In the view of Professor Elaine Manzano, of the Institute of science, technology and quality, everything that involves importing becomes more complex. "Anvisa impose rules governing the distribution and Reckitt will have to fall in order to distribute the medicines in the country," explains the expert.
According to a source connected to Bristol, this movement is part of the company's strategy of focusing on organic products such as anti-retroviral drugs. "The medicines free sales does not have more space for the company. They chose a niche market for the future and already disbanded of various plants. It is likely that in the future, the unit of Mexico also be undone and the company comes out of this market. "
In Brazil, the company faced logistical problems that have resulted in the absence of the drug Naldecon, thus opening space for other energy drink. Through the note, Reckitt said the collaboration will enter into force after regulatory approvals that should occur until the second quarter of the year. According to Rakesh Kapoor, President of Reckitt agreement "is an important step in building our presence in the healthcare market in emerging markets". In addition, the Executive pointed out that the brands have strong margins and with growth potential.
Bristol already explained that "has worked to focus its business around the world, especially in areas of high medical need." The American manufacturer points out that the agreement does not involve any transfer of facilities for Reckitt.
Emerging in high
Aware of the emerging economies, the British Reckitt is willing to focus on this market. The company hopes that by 2015, 50% of its revenues come from this market. And to achieve this result, the company is prepared to make acquisitions this year, to reach a growth of 5% to 6% in its revenue.
According to data released by the company, in 2012, net income totaled r $ 5.6 billion (1.938 billion pounds sterling), a high of 5% compared to the previous year. Similarly, the net revenue advanced 4%, to $ 29.3 billion (9.567 billion GBP).